EnteroMedics Inc (ETRM) : Mpm Asset Management scooped up 9 additional shares in EnteroMedics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 74,215 shares of EnteroMedics Inc which is valued at $12,765.
Other Hedge Funds, Including , Perkins Capital Management Inc reduced its stake in ETRM by selling 21,467 shares or 5.58% in the most recent quarter. The Hedge Fund company now holds 363,413 shares of ETRM which is valued at $79,951. EnteroMedics Inc makes up approx 0.09% of Perkins Capital Management Inc’s portfolio.
EnteroMedics Inc opened for trading at $0.182 and hit $0.184 on the upside on Monday, eventually ending the session at $0.1714, with a gain of 1.42% or 0.0024 points. The heightened volatility saw the trading volume jump to 15,54,964 shares. Company has a market cap of $1.6 M.
Many Wall Street Analysts have commented on EnteroMedics Inc. Shares were Downgraded by ROTH Capital on Jun 9, 2016 to ” Neutral” and Lowered the Price Target to $ 0.50 from a previous price target of $3 .
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology which is referred to as VBLOC therapy is designed to intermittently block the vagus nerve using high frequency low energy electrical impulses. The Company’s initial product is the Maestro System which uses VBLOC therapy to affect metabolic regulatory control limits the expansion of the stomach help control hunger sensations between meals reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product the Maestro Rechargeable System in the United States Australia the European Economic Area and other countries.